+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Uterine Cancer Therapeutics and Diagnostics - Global Strategic Business Report

  • PDF Icon

    Report

  • 173 Pages
  • February 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5141501
The global market for Uterine Cancer Therapeutics and Diagnostics was valued at USD 22.2 Billion in 2024 and is projected to reach USD 28.2 Billion by 2030, growing at a CAGR of 4.1% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Uterine Cancer Therapeutics and Diagnostics Market - Key Trends & Drivers Summarized

Why Is Uterine Cancer Detection and Treatment So Vital?

Uterine cancer, one of the most common cancers affecting women, primarily includes endometrial cancer and uterine sarcomas. Early detection and effective treatment are critical for improving survival rates and quality of life. As the incidence of uterine cancer rises globally, the demand for advanced therapeutics and diagnostics has intensified. Early-stage detection through techniques like transvaginal ultrasound, endometrial biopsy, and advanced imaging methods can significantly improve treatment outcomes. Moreover, personalized treatment approaches, including surgery, radiation therapy, chemotherapy, and hormone therapy, have evolved to target specific cancer types and stages, improving patient outcomes and minimizing side effects. The integration of molecular diagnostics and biomarker testing has further refined the ability to tailor treatments, ensuring that patients receive the most effective therapies based on the genetic makeup of their tumors.

How Are Technological Advancements Revolutionizing Uterine Cancer Care?

Technological innovations have been pivotal in advancing both the diagnosis and treatment of uterine cancer. The advent of minimally invasive surgical techniques, such as robotic-assisted surgery, has reduced recovery times and improved surgical outcomes, offering patients less invasive options with fewer complications. Additionally, the development of targeted therapies and immunotherapies has opened new avenues for treatment, particularly for patients with advanced or recurrent uterine cancer. These therapies work by targeting specific molecules involved in cancer growth, allowing for more precise and effective treatment with fewer side effects compared to traditional chemotherapy. On the diagnostics front, next-generation sequencing (NGS) and liquid biopsies are emerging as powerful tools for identifying genetic mutations and monitoring treatment responses in real-time. These advancements enable clinicians to make more informed decisions, adjust treatments as needed, and provide more personalized care.

What Is Driving the Adoption of Advanced Diagnostics and Therapeutics in Uterine Cancer?

The increasing prevalence of uterine cancer, particularly in aging populations and those with lifestyle-related risk factors, is driving the adoption of advanced diagnostics and therapeutics. As awareness of uterine cancer symptoms and the importance of early detection grows, more women are undergoing regular screenings, leading to earlier diagnosis and better treatment outcomes. Additionally, healthcare providers are increasingly adopting personalized medicine approaches, utilizing genetic and molecular testing to guide treatment decisions. This shift towards precision medicine is supported by the growing body of research linking specific genetic mutations to treatment responses in uterine cancer. Furthermore, the rising healthcare expenditures in developed and emerging markets are enabling greater access to advanced diagnostics and treatments, contributing to improved survival rates and patient outcomes. The expanding role of multidisciplinary care teams, including oncologists, radiologists, pathologists, and genetic counselors, is also enhancing the delivery of comprehensive and coordinated care for uterine cancer patients.

What Factors Are Driving the Growth in the Uterine Cancer Therapeutics and Diagnostics Market?

The growth in the Uterine Cancer Therapeutics and Diagnostics market is driven by several factors, including advancements in diagnostic technologies, the increasing availability of personalized treatment options, and the rising prevalence of uterine cancer worldwide. The ongoing development of molecular diagnostics and biomarker-driven therapies is significantly contributing to market expansion, as these innovations allow for more targeted and effective treatment strategies. Additionally, the growing emphasis on early detection through regular screenings and the use of advanced imaging techniques is increasing the demand for diagnostic services. The rising awareness of uterine cancer and the importance of timely intervention are also driving patient demand for cutting-edge therapies and diagnostics. Furthermore, the increasing healthcare expenditure in both developed and emerging markets is enabling broader access to these advanced technologies, further fueling market growth. Finally, the expanding pipeline of new therapeutics, including targeted therapies and immunotherapies, is expected to continue driving the market as these treatments offer new hope for patients with advanced or resistant forms of uterine cancer.

Report Scope

The report analyzes the Uterine Cancer Therapeutics and Diagnostics market, presented in terms of market value (USD Thousand). The analysis covers the key segments and geographic regions outlined below.

Segments

Cancer Type (Endometrial Carcinomas, Uterine Sarcomas); Segment (Therapeutics, Diagnostics).

Geographic Regions/Countries

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Endometrial Carcinomas Therapeutics & Diagnostics segment, which is expected to reach $19 Billion by 2030 with a CAGR of a 5%. The Uterine Sarcomas Therapeutics & Diagnostics segment is also set to grow at 2.4% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, valued at $5.8 Billion in 2024, and China, forecasted to grow at an impressive 7.5% CAGR to reach $6.4 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in USD from 2024 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as AstraZeneca PLC, BioAtla, BioNTech AG, Eisai Co., Ltd., Hikma Pharmaceuticals PLC and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Uterine Cancer Therapeutics and Diagnostics Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Uterine Cancer Therapeutics and Diagnostics Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Uterine Cancer Therapeutics and Diagnostics Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Some of the 46 major companies featured in this Uterine Cancer Therapeutics and Diagnostics market report include:

  • AstraZeneca PLC
  • BioAtla
  • BioNTech AG
  • Eisai Co., Ltd.
  • Hikma Pharmaceuticals PLC
  • immatics biotechnologies GmbH
  • Imvax
  • Karyopharm Therapeutics, Inc.
  • Schrodinger LLC
  • Sun Pharmaceutical Industries Ltd.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Uterine Cancer Therapeutics and Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Increasing Incidence of Uterine Cancer Driving Demand forg Advanced Therapeutics
  • Rising Adoption of Personalized Medicine in Cancer Treatment
  • Advancements in Genomic Testing Enhancing Early Diagnosis Capabilities
  • Growing Demand for Minimally Invasive Surgical Techniques
  • Development of Targeted Therapies Creating New Market Opportunities
  • Impact of Aging Population on Uterine Cancer Incidence
  • Increasing Investments in Cancer Research and Development
  • Adoption of AI and Machine Learning in Diagnostic Technologies
  • Rising Awareness and Screening Programs Boosting Early Detection Rates
  • Growing Demand for Combination Therapies in Cancer Treatment
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 2: World Historic Review for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 3: World 15-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Uterine Sarcomas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 5: World Historic Review for Uterine Sarcomas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 6: World 15-Year Perspective for Uterine Sarcomas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Endometrial Carcinomas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 8: World Historic Review for Endometrial Carcinomas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 9: World 15-Year Perspective for Endometrial Carcinomas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 10: World Uterine Cancer Therapeutics and Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • Table 11: World Recent Past, Current & Future Analysis for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 12: World Historic Review for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 13: World 15-Year Perspective for Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 15: World Historic Review for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 16: World 15-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • Table 17: USA Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 18: USA Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 19: USA 15-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2015, 2025 & 2030
  • Table 20: USA Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 21: USA Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 22: USA 15-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2015, 2025 & 2030
CANADA
  • Table 23: Canada Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 24: Canada Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 25: Canada 15-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2015, 2025 & 2030
  • Table 26: Canada Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 27: Canada Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 28: Canada 15-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2015, 2025 & 2030
JAPAN
  • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • Table 29: Japan Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 30: Japan Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 31: Japan 15-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2015, 2025 & 2030
  • Table 32: Japan Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 33: Japan Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 34: Japan 15-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2015, 2025 & 2030
CHINA
  • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • Table 35: China Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 36: China Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 37: China 15-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2015, 2025 & 2030
  • Table 38: China Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 39: China Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 40: China 15-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2015, 2025 & 2030
EUROPE
  • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • Table 41: Europe Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 42: Europe Historic Review for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 43: Europe 15-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • Table 44: Europe Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 45: Europe Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 46: Europe 15-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2015, 2025 & 2030
  • Table 47: Europe Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 48: Europe Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 49: Europe 15-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2015, 2025 & 2030
FRANCE
  • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • Table 50: France Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 51: France Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 52: France 15-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2015, 2025 & 2030
  • Table 53: France Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 54: France Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 55: France 15-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2015, 2025 & 2030
GERMANY
  • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • Table 56: Germany Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 57: Germany Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 58: Germany 15-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2015, 2025 & 2030
  • Table 59: Germany Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 60: Germany Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 61: Germany 15-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2015, 2025 & 2030
ITALY
  • Table 62: Italy Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 63: Italy Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 64: Italy 15-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2015, 2025 & 2030
  • Table 65: Italy Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 66: Italy Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 67: Italy 15-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2015, 2025 & 2030
UNITED KINGDOM
  • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • Table 68: UK Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 69: UK Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 70: UK 15-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2015, 2025 & 2030
  • Table 71: UK Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 72: UK Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 73: UK 15-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2015, 2025 & 2030
SPAIN
  • Table 74: Spain Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 75: Spain Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 76: Spain 15-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2015, 2025 & 2030
  • Table 77: Spain Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 78: Spain Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 79: Spain 15-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2015, 2025 & 2030
RUSSIA
  • Table 80: Russia Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 81: Russia Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 82: Russia 15-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2015, 2025 & 2030
  • Table 83: Russia Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 84: Russia Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 85: Russia 15-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2015, 2025 & 2030
REST OF EUROPE
  • Table 86: Rest of Europe Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 87: Rest of Europe Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 88: Rest of Europe 15-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2015, 2025 & 2030
  • Table 89: Rest of Europe Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 90: Rest of Europe Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 91: Rest of Europe 15-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2015, 2025 & 2030
ASIA-PACIFIC
  • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • Table 92: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 93: Asia-Pacific Historic Review for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 94: Asia-Pacific 15-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • Table 95: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 96: Asia-Pacific Historic Review for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Endometrial Carcinomas and Uterine Sarcomas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 97: Asia-Pacific 15-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Endometrial Carcinomas and Uterine Sarcomas for the Years 2015, 2025 & 2030
  • Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 99: Asia-Pacific Historic Review for Uterine Cancer Therapeutics and Diagnostics by Segment - Therapeutics and Diagnostics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 100: Asia-Pacific 15-Year Perspective for Uterine Cancer Therapeutics and Diagnostics by Segment - Percentage Breakdown of Value Sales for Therapeutics and Diagnostics for the Years 2015, 2025 & 2030
AUSTRALIA
  • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
INDIA
  • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Uterine Cancer Therapeutics and Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
IV. COMPETITION

Companies Mentioned

  • AstraZeneca PLC
  • BioAtla
  • BioNTech AG
  • Eisai Co., Ltd.
  • Hikma Pharmaceuticals PLC
  • immatics biotechnologies GmbH
  • Imvax
  • Karyopharm Therapeutics, Inc.
  • Schrodinger LLC
  • Sun Pharmaceutical Industries Ltd.

Table Information